Clinical Outcomes and Correlation with Longitudinal Circulating Tumor (ct)dna Dynamics of a Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-Positive/her2-negative (HR+/HER2−) Advanced or Metastatic Breast Cancer.